MMP9 Double Nickase Plasmid (h): sc-400083-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MMP9 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- MMP9 Double Nickase Plasmid (h) and MMP9 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MMP9. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MMP9 Antibody (E-11): sc-393859
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MMP9 Double Nickase Plasmid (h) | sc-400083-NIC | 20 µg | $410.00 | |||
MMP9 Double Nickase Plasmid (h2) | sc-400083-NIC-2 | 20 µg | $410.00 |
MMP9 (matrix metallopeptidase 9) encodes a secreted zinc-dependent endopeptidase that degrades extracellular matrix components such as type IV collagen and gelatin, coordinating tissue remodeling and basement membrane turnover. MMP9 activity is regulated by activation of its zymogen form and inhibition by TIMPs, linking it to protease networks that modulate cell migration, adhesion dynamics, and inflammatory signaling. It participates in processes including angiogenesis, leukocyte extravasation, and wound repair, and is frequently studied in the context of ECM remodeling programs downstream of cytokines, growth factors, and MAPK/NF-κB signaling. Dysregulated MMP9 expression or activity has been associated with cancer invasion and metastasis biology, cardiovascular remodeling, chronic inflammatory disorders, and neuroinflammation.
MMP9 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MMP9 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MMP9. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MMP9 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MMP9-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.